DRUCK-study Experiences from implementing user survey, rapid testing and risk counselling, involving trained agency staff
|
|
- Winfred Whitehead
- 6 years ago
- Views:
Transcription
1 DRUCK-study Experiences from implementing user survey, rapid testing and risk counselling, involving trained agency staff Ruth Zimmermann Department for Infectious disease epidemiology HIV, AIDS STI and Hepatitis unit Robert Koch Institute Berlin
2 Interventionalpartsofthestudy HIV-rapid testing offered to participants -in supplementtodbs testing Targeted counselling in low-threshold drug services - Short and targeted counselling for knowledge gaps during interview - Training of counsellors HIV/ Hepatitis C test results Provided after 2 weeks during study opening hours Posttest-counselling by trained MD 2 DRUCK-Studie des Robert Koch-Instituts
3 Howtocollectdataon knowledge? Presenttruestatementson HBV, HCV, HIV, theirmodesof transmission and prevention Ex: Hepatitis C can be transmitted by sharing filters. o I knewthisalready o wasn tcleartome o thisisnewtome participant can learn something Ifthisfactisnot clearornew: Propose targeted short counselling 3
4 4
5 Training of staff Awareness rising and training of drug facility staff for possible modes of transmission(hcv) Traditional HIV prevention approaches are not sufficient Transmission of HCV via filters, spoons, shared water Training ofstaffforclinicalcourse, therapeuticoptionsofhbv, HCV, HIV Find collaborating partners(local AIDS Hilfe..) Encourage drug facility staff to intervene in a targeted and brief way 5
6 Targeted counselling as short intervention in low threshold drug services targeted counselling % 80% 77% 65% % 43% 0 Leipzig (n=130) Hanover (n=252) Munich (n=235) Frankfurt (n=285) Hamburg (n=319) Cologne (n=322) 6
7 HIV rapid testing offered 4/4 days /week, coop. with localaids Hilfe, +++ engaged staff 46.0 offered 4/4 days /week, +++ Engaged MD offered 2/4 days/week, coop. with localaids Hilfe +++ engaged staff offered 4/4 days/week 2 study sites, Crack scene offered 4/4 days/week, Crack scene offered outside of study hours Leipzig (n=130) 32.0 Hanover (n=252) 23.0 Munich (n=235) 18.0 Frankfurt (n=285) 6.0 Hamburg (n=319) 1.3 Cologne (n=322) 7
8 Conclusions Whatdoesnot workwell? posttest counselling after several days Appointment-based interventions General traditional (risk) counselling Longerinterventions(> 10 minutes) What works well? Knowledge data collection by true statements Brief and targeted interventions(5-10 min) On site and risk related counselling HIV rapid testing(free, anonymous), combined with counselling Integrated and combined approaches, adapted to local conditions 8
9 Whatareyourexperiences? 9
10 10
11 Discussion: how to improve effectiveness of prevention of infectious diseases? Present results to local department of health and drug helping system, discuss further steps Adress drug users with messages HIV: PEP is possible HIV: treatment is primary prevention HCV: look for neglected risks: straws, filters, spoons, HBV: get vaccinated 11
12 Discussion: how to improve effectiveness of prevention of infectious diseases? Adress GPs and low threshold medical care HBV: check, vaccinate, vaccinate, vaccinate (don t forget booster vaccination) Testing combined with counseling: HCV-antibody testing and RNA-testing!
13 Discussion: how to improve effectiveness of prevention of infectious diseases? Adress prisons and drug helping units Access to information and materials (needles, disinfectants,...) Last but not least: Adopt prevention strategies to local conditions
14 DRUCK-Study (DrogenundchronischeInfektionskrankheiten) Objectives TodetermineHIV, HBC, HCV andhtlv prevalenceamong current IDU in selected German cities Collection of representative KABP data, determining risk profiles ToimprovepreventionofHIV andhepatitisamongpwid in Germany Design Multicentre cross-sectional study Sero- and behavioural survey Sample size: 2,034 IVD (reached: IVD in 8 cities) 14
15 Methods Mapping ofdrugscenein cities Close co-operation with local low-threshold drug services Respondent driven sampling Data: Questionnaire-assisted interviews trained interviewers min. interview anonymised Capillary dried blood spots(dbs) Anti HIV Elisa/Blot Anti HCV Elisa/Blot + HCV-RNA + genotyping (HBsAg+) AntiHBs(titre) + AntiHBc+ HBV-DANN Anti HTLV 15
16 Studienstadt Berlin (n=337) Essen (n=197) Leipzig (n=130) Frankfurt a. M. (n=285) Köln (n=322) Hannover (n=252) München (n=235) Hamburg (n=319) HIV-Schnelltest- Angebot Kein Angebot?? An 4 von 4 Studientage n An 4 von 4 Studientagen Nur außerhalb d. Studienzeiten An 4 von 4 Studientagen An 2 von 4 Studientagen An 4 von 4 Studientagen Anzahl der durchgeführten HIV-Schnelltest Anzahl der Beratungen im Rahmen der Studie Kein Angebot?? 60 (46%) 51 (18%) 4 (1,3%) 80 (32%) 53 (23%) 18 (6%) / 5 k. A. 13 (4%) (FG18)???? 93 (72%) 85 (30%) 209 (65%) 201 (80%) 182 (77%) 138 (43%) Anzahl der versandten Befunde???? 115 (88%) 216 (76%) 271 (84%) 193 (77%) 199 (85%) 197 (62%) Anzahl der abgeholten Befunde 10???? k. A. 25 (9%) (bis ) ca. 22 (11%) 60 (30%) (8-10%) 16
17 Studienstadt Leipzig (n=130) Frankfurt a. M. (n=285) Köln (n=322) Hannover (n=252) München (n=235) Hamburg (n=x ) HIV-Schnelltest- Angebot An 4 von 4 Studientagen An 4 von 4 Studientagen Nur außerhalb der Studienzeiten An 4 von 4 Studientagen An 2 von 4 Studientagen An 4 von 4 Studientagen Anzahl der durchgeführten HIV- Schnelltest 60 (46%) 51 (18%) 4 (1,3%) 80 (32%) 53 (23%) XX (XX%) Anzahl der Beratungen im Rahmen der Studie 93 (72%) 85 (30%) 209 (65%) 201 (80%) 182 (77%) 17
Wenz et al. BMC Public Health (2016) 16:927 DOI /s
Wenz et al. BMC Public Health (2016) 16:927 DOI 10.1186/s12889-016-3545-4 RESEARCH ARTICLE Open Access High variability of HIV and HCV seroprevalence and risk behaviours among people who inject drugs:
More informationGovernment of Canada Federal AIDS Initiative Milestones
HIV in Canada: Trends and Issues for Advancing Prevention, Care, Treatment and Support Through Knowledge Exchange Michael R Smith, Senior Policy Advisor, Programs and Coordination Division, Centre for
More informationStrategies of drug users to avoid infection with hepatitis C
With financial support from the Drug Prevention and Information Programme of the European Union Strategies of drug users to avoid infection with hepatitis C Results from five European countries Dr. Heike
More informationThe new German strategy on HIV, Hepatitis B, C and STI, an integrated approach. Ines Perea Ministry of Health, Germany
The new German strategy on HIV, Hepatitis B, C and STI, an integrated approach Ines Perea Ministry of Health, Germany Reasons for a new strategy in 2016 New international agreements (SDG s) Renewed political
More informationGERMANY 2015 NATIONAL REPORT (2014 data) to the EMCDDA by the Reitox National Focal Point. Workbook Harms and Harm Reduction
GERMANY 2015 NATIONAL REPORT (2014 data) to the EMCDDA by the Reitox National Focal Point Workbook Harms and Harm Reduction Tim Pfeiffer-Gerschel, Lisa Jakob, Esther Dammer & Krystallia Karachaliou, IFT
More informationHIV in Prison Situation in Frankfurt am Main
HIV in Prison Situation in Frankfurt am Main European Project ROME-SEMINAR, May 14.-15., 2008 Horst Herkommer, Sella Oneko Praxis Psychosoziale Beratung Frankfurt am Main Germany General remark: Situation
More informationHepatitis prevention in the context of HIV prevention point work in Latvia
Hepatitis prevention in the context of HIV prevention point work in Latvia Līva Grāmatiņa Centre for disease prevention and control of Latvia 9..205. HIV prevention point network in Latvia: History; Location;
More informationHepatitis C : Screening and Prevention Strategies
Hepatitis C : Screening and Prevention Strategies JAMEELA J. YUSUFF, MD MPH FACP MEDICAL DIRECTOR STAR HEALTH CENTER AT SUNY DOWNSTATE MEDICAL CENTER JANUARY 24, 2018 Overview Review of Screening Guidelines
More informationPoland nationalupdate
Poland nationalupdate 16th October 2014 Annual expert meeting on Drug-related deaths (DRD) and Drug-related infectious diseases (DRID) Estimation of HIV and HCV prevalence among injecting drug users in
More informationThe Hepatitis B-e antigen-positive
The Hepatitis B-e antigen-positive Dental Student Developing an Equitable Policy Hepatitis B Virus Serology 1 HBsAg A protein on the surface of HBV; it can be detected in high levels in serum during acute
More informationProvincial Infectious Diseases Advisory Committee Public Health Response to Hepatitis C
Provincial Infectious Diseases Advisory Committee Public Health Response to Hepatitis C Dr. Doug Sider, Medical Director, Public Health Ontario Dr. Peggy Millson, Professor Emeritus, Dalla Lana School
More informationDetection of Hepatitis B and C in Primary Care
Detection of Hepatitis B and C in Primary Care Presentation 2 January 2016 Quality Quality Education Education for for aa Healthier Healthier Scotland Scotland 1 1 Learning Outcomes Participants will be
More informationPrevention of and Immunisation against Hepatitis B and C
Prevention of and Immunisation against Hepatitis B and C January 2014 Quality Education for a Healthier Scotland 1 Learning Outcomes Participants will be able to:- Demonstrate an increased knowledge and
More informationA Sexual Health Study with Africans in Frankfurt am Main
A Sexual Health Study with Africans in Frankfurt am Main Working together for Health Promotion INFORMATION FOR STUDY PARTICIPANTS WHO ARE WE? We are a group of Africans, researchers and persons doing
More informationPrimary Care Services for blood borne viral hepatitis prevention, treatment and care
Primary Care Services for blood borne viral hepatitis prevention, treatment and care Author: Josie Smith, Marion Lyons Page 1 of 13 October 2006 Status : Final Contents: Page: Executive Summary 3 Introduction
More informationPromoting hepatitis B vaccination
Promoting hepatitis B vaccination Introduction Hepatitis B is a serious blood borne infection that can exacerbate hepatitis C infection, can cause serious liver damage and sometimes results in death. Hepatitis
More informationSigns of success latest national NESI data?
Needle Exchange Surveillance Initiative Signs of success latest national NESI data? Alison Munro (University of the West of Scotland) Study partners Professor Avril Taylor Chief Investigator (UWS) Dr Alison
More informationFormative Research results
FRR Annex 5: Presentation of the FR results in the project meeting, Berlin, 11. 13.02.2013 Formative Research results Sandra Dudareva Vizule, Ulrich Marcus Robert Koch Institute 11 February 2013 Content
More informationToronto Declaration: Strategies to control and eliminate viral hepatitis globally. A call for coordinated action
Toronto Declaration: Strategies to control and eliminate viral hepatitis globally A call for coordinated action Hepatitis B National Action Plan All countries should develop a national and/or regional
More informationHEPATITIS C, ACUTE CRUDE DATA. Number of Cases 5 Annual Incidence a LA County 0.05 California b 0.10 United States b 0.68 Age at Diagnosis Mean 38
2016 Annual Morbidity Report HEPATITIS C, ACUTE a Rates calculated based on less than 19 cases or events are considered unreliable b Calculated from: CDC. Notice to Readers: Final 2016 Reports of Nationally
More informationNew Brunswick Report on Sexually Transmitted and Blood Borne Infections, 2016
New Brunswick Report on Sexually Transmitted and Blood Borne Infections, 6 Table of Contents. Introduction.... Methodology... 3. Data Limitations.... Definitions used... 3 5. Overview of STBBI epidemiology
More informationPrevention of Hepatitis in risk groups and hepatitis and HIV in Albania. Ass.Prof. Najada COMO
VHPB Meeting Prevention of Hepatitis in risk groups and hepatitis and HIV in Albania Ass.Prof. Najada COMO Infectious Diseases Clinic UHC Mother Theresa Tirane Rogner, Tirane, Albania, 27 28 October 2016
More informationQuADS Organisational Standards and Professional Competencies in needle exchange
QuADS Organisational Standards and Professional Competencies in needle exchange N This briefing paper was funded by the Department of Health as part of their 'Making Harm Reduction Work' initiative. DrugScope/Department
More informationViral Hepatitis. WHO Regional Office for Europe July 2013
Viral Hepatitis WHO Regional Office for Europe July 2013 What is Hepatitis? Hepatitis is a viral infection that causes inflammation of the liver There are five main types of viral hepatitis: A, B, C, D,
More informationBC Enhanced Hepatitis Strain Surveillance Project Hepatitis B. Acute HBV Questionnaire
BC Enhanced Hepatitis Strain Surveillance Project Hepatitis B Informed Consent: Please read to individual and answer any questions There are about 60,000 people with hepatitis B in BC. We want to find
More informationFeedback from joint country mission on HIV and hepatitis B and C of ECDC and EMCDDA experts to Latvia, September 2014
Feedback from joint country mission on HIV and hepatitis B and C of ECDC and EMCDDA experts to Latvia, September 2014 Dr. Nicole Werner-Keišs Lisbon, 16.10.2014 Outline Background, scope and objectives
More informationDevelopment of hepatitis B prevention in Germany the first ten years
VHPB meeting 2003 Prevention of viral hepatitis in Germany and Scandinavia: lessons learnt and the way forward Berlin, October 13-14 Development of hepatitis B prevention in Germany the first ten years
More informationHIV, HBV and HCV testing policy experiences and lessons learned.
HIV, HBV and HCV testing policy experiences and lessons learned. Contents HIV and viral hepatitis: distinct epidemics at different stages of evolution Epidemiology: transmission, prevalence, incidence
More informationGreater Glasgow and Clyde. Blood Borne Viruses: Some important basic facts
Greater Glasgow and Clyde Blood Borne Viruses: Some important basic facts Greater Glasgow and Clyde Blood Borne Viruses: Some important basic facts A programme developed by Greater Glasgow and Clyde Health
More informationFunding of patient-oriented clinical research by the German Federal Ministry of Education and Research (BMBF)
Funding of patient-oriented clinical research by the German Federal Ministry of Education and Research (BMBF) Dr. Steinmüller/ Dr. Jacobs July 8th, 2011, Cologne Overview Health research programme of the
More informationPrevention of and Immunisation against Hepatitis B and C
Prevention of and Immunisation against Hepatitis B and C Presentation 5 October 2018 0 Learning Outcomes Participants will be able to: Demonstrate an increased knowledge and understanding of opportunities
More informationEpidemiology of Acute Hepatitis C Infection in Canada Results from the Enhanced Hepatitis Strain Surveillance System (EHSSS)
Epidemiology of Acute Hepatitis C Infection in Canada Results from the Enhanced Hepatitis Strain Surveillance System (EHSSS) At a Glance Reported rates of acute HCV declined from.5 per, population in to.
More informationELIMINATION OF VIRAL HEPATITIS IN ROMANIA LESSONS LEARNT AND THE WAY FORWARD
ELIMINATION OF VIRAL HEPATITIS IN ROMANIA LESSONS LEARNT AND THE WAY FORWARD 17 May 2018 Bucharest, Romania Organisers Associations Collaborating on Hepatitis to Immunize and Eliminate the Viruses in Europe
More informationEAST LONDON INTEGRATED CARE
CITY & HACKNEY ELIC EAST LONDON INTEGRATED CARE MANAGEMENT OF CHRONIC HEPATITIS B IN PRIMARY CARE Chronic Hepatitis B virus (HBV) is an important public health problem globally and a leading cause of liver
More informationKAZAKHSTAN. National Focal Point. Drug Abuse and Drug Dependence Treatment Situation. Territory : 2,717,300 km 2 Capital: Astana BASIC DATA
KAZAKHSTAN Territory : 2,717,300 km 2 Capital: Astana Map No. 3771 Rev. 6 UNITED NATIONS January 2004 BASIC DATA Total population (millions) 2009 15.5* Population under age15 (as % of total) 2010 23.8*
More informationItem 4. Sexual Health and Blood Borne Virus Strategy Strategy for Sexual Health and Blood Borne Viruses. Background
Item 4 Strategy for Sexual Health and Blood Borne Viruses Background 1. In August 2011 the Scottish Government launched a joint Sexual Health and Blood Borne Virus Framework. This brought four policy areas
More informationMethods: respondent driven sampling (RDS) was used to recruit PWID
RDS study among PWID in Kohtla-Järve, north-east of Estonia: prevalence of HIV and risk behaviours (an update, based on 216 study, and methodological considerations) Maris Salekešin Sigrid Vorobjov Methods:
More informationHepatitis C Best Practice Guidelines For Local Health Departments
Hepatitis C Best Practice Guidelines For Local Health Departments LHDs are responsible for investigating and reporting all physician reported cases of acute hepatitis C (HCV). For clients known to have
More informationHEPATITIS A & B VACCINATION
HEPATITIS A & B VACCINATION What is Hepatitis A? Hepatitis A is a liver infection caused by the Hepatitis A virus. It is spread in the faeces of an infected person. The virus can spread through contaminated
More informationGERMANY 2016 NATIONAL REPORT (2015/2016 data) to the EMCDDA by the Reitox National Focal Point. Workbook Harms and Harm Reduction
GERMANY 2016 NATIONAL REPORT (2015/2016 data) to the EMCDDA by the Reitox National Focal Point Workbook Harms and Harm Reduction Esther Dammer, Loretta Schulte, Krystallia Karachaliou & Tim Pfeiffer-Gerschel
More informationOpportunities For Hepatitis C Modalities in Substance Use Treatment Settings
Opportunities For Hepatitis C Modalities in Substance Use Treatment Settings KATIE BURK, MPH VIRAL HEPATITIS COORDINATOR SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH 1 Webinar Outline 1. HCV Overview 2. SFDPH
More informationEffective Date: 6/10/2013 Review Date: 6/10/2016
Policy Title: Sterilization and Disinfection of Patient-Care Items Policy Number: 11 6.2.2. Examples of useful items to maintain in the office sterilization log are as following: o Date and time of cycle
More informationMulticenter comparison of genotypic tropism testing: results from viral RNA and proviral DNA
HIV Genotypischer Resistenzalgorithmus Deutschland Multicenter comparison of genotypic tropism testing: results from viral RNA and proviral DNA Financial disclosure Study was financially supported by ViiV
More informationHealth Care Workers and Viral Hepatitis in Turkey. Bulent Degertekin M.D. Viral Hepatitis Prevention Board Meeting
Different Aspects of Viral Hepatitis Health Care Workers and Viral Hepatitis in Turkey Bulent Degertekin M.D. Viral Hepatitis Prevention Board Meeting 12 13 November 2009 Istanbul. Turkey Hepatitis B and
More informationPrevalence of HIV and risk behaviors among injecting drug users in Tallinn, Estonia in a series of cross-sectional studies
Prevalence of HIV and risk behaviors among injecting drug users in Tallinn, Estonia in a series of cross-sectional studies Sigrid Vorobjov 1, Maris Salekešin 1, Katri Abel-Ollo 1, Anneli Uusküla 2, Don
More informationProposed 1 st IS for Hepatitis E Virus RNA WHO/BS/
www.pei.de Proposed 1 st IS for Hepatitis E Virus RNA WHO/BS/09.2126 S. Baylis, Division of Virology, Paul-Ehrlich-Institut, Langen, Germany SoGAT XXII 14 th -15 th April 2011, Rome, Italy Presented at:
More informationGet Hip to Hep: Partnerships for Prevention
Get Hip to Hep: Partnerships for Prevention California Immunization Coalition Summit, Sacramento, May 3, 2010 Overview 1. Introduce the California Adult Viral Hepatitis Prevention Strategic Plan 2. Highlight
More informationHepatitis B Virus and the Opioid Crisis
Hepatitis B Virus and the Opioid Crisis Alice Asher, RN, Ph.D. Epidemiology and Surveillance Branch Division of Viral Hepatitis National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Centers
More informationRisk Factors for HCV Transmission in Pakistan
Risk Factors for HCV Transmission in Pakistan Dr. Saeed Hamid Professor & Chair Department of Medicine Aga Khan University Karachi, Pakistan President, PSSLD Modes of transmission of HCV in Pakistan. Only
More informationCITY & HACKNEY ELIC EAST LONDON INTEGRATED CARE MANAGEMENT OF CHRONIC HEPATITIS B IN PRIMARY CARE
CITY & HACKNEY ELIC EAST LONDON INTEGRATED CARE MANAGEMENT OF CHRONIC HEPATITIS B IN PRIMARY CARE Chronic Hepatitis B virus (HBV) is an important public health problem globally and a leading cause of liver
More informationDr Vivian Hope. Health Protection Agency, London. 19 th Annual Conference of the British HIV Association (BHIVA)
19 th Annual Conference of the British HIV Association (BHIVA) Dr Vivian Hope Health Protection Agency, London 16-19 April 2013, Manchester Central Convention Complex Prevalence of, and risk factors for,
More informationDetection of Hepatitis B and C in Primary Care
Detection of Hepatitis B and C January 2014 Quality Education for a Healthier Scotland 1 Learning Outcomes Participants will be able to:- Identify groups of people who have a higher prevalence of Hepatitis
More information2016 NYS HIV Quality of Care Review
2016 NYS HIV Quality of Care Review A new way forward in four parts Bruce Agins, MD, MPH Medical Director NYSDOH AIDS Institute December 15, 2016 Ending the Epidemic: update! A 3-Point plan announced by
More informationOverall aim Improving the access to and the quality of health and social services for marginalised people
Overall aim Improving the access to and the quality of health and social services for marginalised people To tackle health inequalities and to improve prevention, care and treatment services, targeting
More informationEC CERTIFICATE. National Institute for Biological Standards and Control (NIBSC) Blanche Lane South Mimms Potters Bar Hertfordshire EN6 3QG UK
National Institute for Biological Standards and Control (NIBSC) EC Certificate - Full Quality Assurance System Approval Certificate Annex IV (excluding sections 4 and 6) of Council Directive 98/79/EC on
More informationYou re not alone LIVING WITH HEPATITIS C
HCV_2063_PIB_E03.indd 1 You re not alone LIVING WITH HEPATITIS C HCV_2063_PIB_E03.indd 2 HAVE HEPATITIS C? READ THIS BROCHURE! And learn more about it. DON T HAVE HEPATITIS C? READ THIS BROCHURE ANYWAY!
More informationThe Counselling of Blood Donors Identified as HIV Reactive. A Review as from January 2007 until June 2011
The Counselling of Blood Donors Identified as HIV Reactive A Review as from January 2007 until June 2011 The Blood Transfusion Service of Namibia Dr. Regine Redecker Mr. Tinus Matyayi 2 3 Background -TTI
More informationNotes Detection of Hepatitis B and C in Primary Care
Health Protection Scotland/NHS Education Scotland January 2016 Injecting drug use is the commonest route of transmission in Scotland and the UK. Sharing of any of the equipment used to inject drugs can
More informationPrevention and control of viral hepatitis: Role and impact of liver patient groups in Europe. The Netherlands National hepatitis Centre
Prevention and control of viral hepatitis: Role and impact of liver patient groups in Europe. The Netherlands National hepatitis Centre 1) History of the organisation(s) Founded in 1997 by: Dutch liver
More informationSexually Transmitted Infections in Vulnerable Groups. Kevin Rebe
Sexually Transmitted Infections in Vulnerable Groups Kevin Rebe Definition: Key Populations Key populations are: Defined groups who, due to specific higher-risk behaviours, are at increased Men risk who
More informationOST saves lives it s official! OST a key to HIV prevention Opioid Substitution Treatment in Germany A Story of Success
XVIII International AIDS Conference, 2010 Vienna UNODC-GTZ Satellite Symposium: OST saves lives it s official! OST a key to HIV prevention Opioid Substitution Treatment in Germany A Story of Success Joerg
More informationDISCLOSURE ESPACE GAIA, FIRST DCR IN PARIS SINCE OCTOBER /06/2017
ESPACE GAIA, FIRST DCR IN PARIS SINCE OCTOBER 2016 First results and perspectives DISCLOSURE DR Elisabeth AVRIL Presentation : Espace GAIA, first DCR in Paris : first results and perspectives Mundipharma,
More informationAustralian Research Centre in Sex, Health & Society. EMBARGOED until am 4/8/09 Secondary Students and Sexual Health 2008
Australian Research Centre in Sex, Health & Society EMBARGOED until 10.30 am 4/8/09 Secondary Students and Sexual Health 2008 Melbourne, Australia Sample 2002 2008 Jurisdictions All All School sectors
More informationUnderstanding your epidemic: WHO tools for hepatitis surveillance
. Understanding your epidemic: WHO tools for hepatitis surveillance Dr Antons Mozalevskis / WHO Regional Office for Europe Dr Yvan Hutin / Global Hepatitis Programme, WHO Headquarters 25 October 2018,
More informationGlobal Reporting System for Hepatitis (GRSH) An introduction. WHO Global Hepatitis Programme
Global Reporting System for Hepatitis (GRSH) An introduction WHO Global Hepatitis Programme 2018 Objectives 1. Explain the role of the new reporting system 2. Outline the reporting required from countries
More informationMost recent data, analyses and feed-back from the 2016 DRID national updates
Most recent data, analyses and feed-back from the 216 DRID national updates Eleni Kalamara, Dagmar Hedrich, Linda Montanari, Isabelle Giraudon 15-16 June 217, Lisbon DRID/TDI annual expert meeting DRID
More informationHEALTH SERVICES POLICY & PROCEDURE MANUAL
PAGE 1 of 5 PURPOSE To provide guidelines on the treatment and care of patients with Hepatitis. POLICY Hepatitis is an injury to hepatic cells and an inflammatory process in the liver. The major causes
More informationHarms and harm reduction workbook. Country X
Harms and harm reduction workbook Country X 1 Table of Contents T0. Summary... 3 T1. National profile... 3 T1.1 Drug-related deaths... 3 T1.2 Drug related acute emergencies... 4 T1.3 Drug related infectious
More informationPrevention of and Immunisation against Hepatitis B and C
Prevention of and Immunisation against Hepatitis B and C Presentation 5 January 2016 Quality Education for a Healthier Scotland 1 Learning Outcomes Participants will be able to:- Demonstrate an increased
More informationVHPB MEETING ANTWERP 2014 ACHIEVEMENTS AND CHALLENGES IN PREVENTION AND CONTROL OF VIRAL HEPATITIS
POST-IT @ VHPB MEETING ANTWERP 2014 ACHIEVEMENTS AND CHALLENGES IN PREVENTION AND CONTROL OF VIRAL HEPATITIS East challenges Risk group vaccination problems Problems of anti-vaccine lobby Importance of
More informationALASKA NATIVE MEDICAL CENTER SEXUALLY TRANSMITTED DISEASE SCREENING AND TREATMENT GUIDELINES
ALASKA NATIVE MEDICAL CENTER SEXUALLY TRANSMITTED DISEASE SCREENING AND TREATMENT GUIDELINES A. Screening Page Chlamydia and Gonorrhea 1 HIV 1 Syphilis 1 Genital Herpes 2 Hepatitis A 2 Hepatitis B 2 Hepatitis
More informationModels of good practice in drug treatment in Europe. Project group
Models of good practice in drug treatment in Europe ( moretreat 2006329 ) Project group Hamburg, London, Rome, Stockholm, Vienna, Warsaw, Zurich Project duration: 17 months from April 2006 August 2008
More informationAdditional North Carolina Projects
Additional North Carolina Projects William Zule, Dr.P.H. www.rti.org RTI International is a trade name of Research Triangle Institute Risk Groups Injecting drug users (IDUs) Non-injecting drug users (non-idus)
More informationHepatitis B stigma by association with HIV in Zambia
Hepatitis B stigma by association with HIV in Zambia Michael Vinikoor 1,2, Annie Kanunga 1, Jodie Dionne-Odom 2, Janet Turan 2, and Edford Sinkala 1,3 1 TROPGAN, Department of Medicine, University of Zambia
More informationArm yourself against Hep B! Vaccinate
Arm yourself against Hep B! Vaccinate Arm yourself against Hep B! Vaccinate Written by Injecting Drug Users for Injecting Drug Users Why it s important for injecting drug users to know about and understand
More informationHIV and Hepatitis C Infection among Persons who Inject Drugs: Global Overview and Policy Implications
HIV and Hepatitis C Infection among Persons who Inject Drugs: Global Overview and Policy Implications Don Des Jarlais, Ph.D. Professor of Psychiatry, Icahn School of Medicine at Mount Sinai UNODC 2014
More informationPatient-Centered Hepatitis C Virus (HCV) Care Via Telemedicine for Individuals on Opiate Agonist Treatment Marija Zeremski, PhD
Patient-Centered Hepatitis C Virus (HCV) Care Via Telemedicine for Individuals on Opiate Agonist Treatment Marija Zeremski, PhD Project Director Clinical Directors Network, Inc. Training Overview Brief
More informationJackie Williams BBV/Sexual Health Trainer
Jackie Williams BBV/Sexual Health Trainer HEPATITIS The Basics What does your liver do? FUNCTIONS n storage of substances - glycogen, iron and vitamins n disposal of metabolic wastes - urea and bile n
More informationHarm reduction among drug users in Spain
Harm reduction among drug users in Spain Luxemburg,, 27 October 21 Dr. José Manuel Arroyo Cobo Deputy Director General of Health in Prisons Ministry of Internal Affairs Dr. Tomás s Hernández ndez Fernández
More informationMonitoring Viral Hepatitis Elimination Generating Reliable Estimates of Hepatitis C Prevalence
Monitoring Viral Hepatitis Elimination Generating Reliable Estimates of Hepatitis C Prevalence Ida Sperle-Heupel Department for Infectious Disease Epidemiology Robert Koch Institute Epidemiological context
More informationExploring the risks of liver cancer after successful treatment for hepatitis C virus
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Exploring the risks of liver cancer after successful treatment for hepatitis C virus 11 June 2013 In Canada and other high-income countries,
More informationGroups at risk for hepatitis B infection - who should be vaccinated
Groups at risk for hepatitis B infection - who should be vaccinated male homosexuals heterosexuals with multiple sex partners (e.g. sex workers) travelers to areas of high HBV endemicity immigrants and
More informationRevised April WGH ER #5 Hospital Rd. Whitehorse Phone: (867) Outside of Whitehorse: Local Community Health Centre/Clinic/ER
Where to access care Who to consult and when Please consult whenever questions arise on how to proceed with postexposure management and when exposure is beyond the scope of guidelines. Blood and Body Fluid
More informationTo provide the guidelines for the management of healthcare workers who have had an occupational exposure to blood and/or body fluids.
TITLE/DESCRIPTION: MANAGEMENT OF OCCUPATIONAL EXPOSURE TO HBV, HCV, and HIV INDEX NUMBER: EFFECTIVE DATE: APPLIES TO: ISSUING AUTHORITY: 01/01/2009 01/01/2013 All GCC Countries GULF COOPERATION COUNCIL
More informationEMCDDA DOCUMENTS ON IMPROVING COMPARABILITY - DRUG-RELATED INFECTIOUS DISEASES
EMCDDA DOCUMENTS ON IMPROVING COMPARABILITY - DRUG-RELATED INFECTIOUS DISEASES 1. Draft guidelines key indicator infections 2. Infection Indicator Map 3. Standard table 09-INFECTIONS-2000 EMCDDA / 2000
More informationAs a result of this training, participants will be able to:
Addressing Sexual Risk with Drug Users and their Partners 1 Day Training This one-day training will build participant knowledge and skills in offering sexual harm reduction options to substance users.
More informationChiang Mai University/Johns Hopkins University HIV/AIDS Research on VCT
Chiang Mai University/Johns Hopkins University HIV/AIDS Research on VCT David Celentano, Professor of Epidemiology May 26, 2005 Scope of the CMU/JHU Collaborative HIV/AIDS Research Agenda HIV/AIDS research
More informationThe HIV Prevention England programme: what s next? Cary James May 2016
The HIV Prevention England programme: what s next? Cary James May 2016 Summary Programme objectives Campaign evolution Sector development Structure and governance Support for HIV prevention system Communication
More informationHepatitis Case Investigation
* indicates required fields Does patient also have: Hepatitis Case Investigation West Virginia Electronic Disease Surveillance System Division of Surveillance and Disease Control Infectious Disease Epidemiology
More informationIntegrating Surveillance - Essential Constituent for HIV/AIDS, Viral Hepatitis, and STDs Control and Prevention
Integrating Surveillance - Essential Constituent for HIV/AIDS, Viral Hepatitis, and STDs Control and Prevention Michael Favorov MD, Ph.D., D.Sc., Harold Margolis MD, CDC Central Asia Program, DIH, EPO;
More informationEpidemiology of Hepatitis B &C in Latvia
Epidemiology of Hepatitis B &C in Latvia Centre for Disease Prevention and Control of Latvia 2015 November 19 Content B/C hepatitis number of cases and incidence rates B/C hepatitis by age and gender Transmission
More informationCitiWide Harm Reduction
CitiWide Harm Reduction Ryan White Part A Harm Reduction Services: AOD Services Conflict of Interest Disclosure: CitiWide Harm Reduction currently has an HRR contract: 07-HRR HRR-748 Presentation to the
More informationمواجهه شغلی HBV HCV HIV
مواجهه شغلی HBV HCV HIV شبكھ جھاني تزریق ایمن تخمین مي زندكھ میلیاردتزریق سالیانھ دردنیاانجام مي شود. تقریبا شانزده خیلي ازاین تزریقھا غیرضروري داروھاي خوراكي بھتر اثرمي كنند بخصوص است وقتي كھ درسال 2000
More informationThe Alphabet Soup of Viral Hepatitis Testing
The Alphabet Soup of Viral Hepatitis Testing August 18, 2011 Patricia Slev, PhD, DABCC Medical Director, Serologic Hepatitis and Retrovirus Laboratory, ARUP Laboratories Assistant Professor of Pathology,
More informationUpdate on Community-based harm reduction services in Nelson Mandela Bay 25/10/2018
Update on Community-based harm reduction services in Nelson Mandela Bay 25/10/2018 Overview Background to injecting drug use Overview of harm reduction Data on Hepatitis Summary of services provided by
More informationBlood Donor Counselling
Blood Donor Counselling A presentation for the Nepal Red Cross Society Blood Transfusion Service Dr Che Kit Lin On behalf of GAP and Hong Kong Red Cross 26 th August 2014 Purpose and Outcomes of Workshop
More informationHepatitis C Basics. Michael Bailey Director of Programming, CATIE. Mary Choy Regional Health Education Coordinator, CATIE
Hepatitis C Basics Michael Bailey Director of Programming, CATIE Mary Choy Regional Health Education Coordinator, CATIE CATIE Our History Learning Objectives 1) To learn about the basics of hepatitis C
More informationInternational Social Work, January, 2014 Human Rights & Social Justice. Lauren Lascher Dr. Elisabeth Reichert
+ International Social Work, January, 2014 Human Rights & Social Justice Lauren Lascher Dr. Elisabeth Reichert + Munich is the capital and largest city of the German state of Bavaria. It is located on
More informationHIV Basics: Clinical Tests and Guidelines
HIV Basics: Clinical Tests and Guidelines ACTHIV 2010 Zelalem Temesgen MD Mayo Clinic Topics Baseline laboratory evaluation Laboratory monitoring through the continuum of care Patients not on antiretroviral
More information